Wolterman Dan

SEC source: 0001193125-26-257953 · ownership.xml · derivative · entry 1

Wolterman Dan · CIK 0001586330 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 52,600

Underlying: Class A Common Stock · 52,600 shares

Expires 2036-06-03

F1 · derivative.exercise_date: The shares underlying this option vest on the date of the Issuer's next regular annual stockholders meeting, subject to Mr. Wolterman's continued service through the applicable vesting date.

SEC source: 0001193125-26-237052 · ownership.xml · derivative · entry 1

Wolterman Dan · CIK 0001586330 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 157,700

Underlying: Class A Common Stock · 157,700 shares

Expires 2036-05-22

F1 · derivative.exercise_date: The shares underlying this option vest on the date of the Issuer's next regular annual stockholders meeting, subject to Mr. Wolterman's continued service through the applicable vesting date.

SEC source: 0001193125-26-021181 · ownership.xml · derivative · entry 1

Wolterman Dan · CIK 0001586330 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 15,000

Underlying: Class A Common Stock · 15,000 shares

Expires 2036-01-21

F1 · derivative.exercise_date: These options were granted on January 21, 2026, and will vest on January 1, 2027.

SEC source: 0000950170-25-083028 · ownership.xml · derivative · entry 1

Wolterman Dan · CIK 0001586330 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 81,817

Underlying: Class A Common Stock · 81,817 shares

Expires 2035-06-05

F1 · shares: The shares underlying this option vest on the date of the Issuer's next regular annual stockholders meeting, subject to Mr. Wolterman's continued service through the vesting date. During the vesting term of the option, Mr. Wolterman will not receive cash compensation for his service as Chairperson of the Board of Directors.

F1 · derivative.exercise_date: The shares underlying this option vest on the date of the Issuer's next regular annual stockholders meeting, subject to Mr. Wolterman's continued service through the vesting date. During the vesting term of the option, Mr. Wolterman will not receive cash compensation for his service as Chairperson of the Board of Directors.

SEC source: 0000950170-25-075372 · ownership.xml · derivative · entry 1

Wolterman Dan · CIK 0001586330 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 79,200

Underlying: Class A Common Stock · 79,200 shares

Expires 2035-05-20

F1 · derivative.exercise_date: The shares underlying this option vest on the date of the Issuer's next regular annual stockholders meeting, subject to Mr. Wolterman's continued service through the applicable vesting date.

SEC source: 0000950170-25-047019 · ownership.xml · derivative · entry 1

Wolterman Dan · CIK 0001586330 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 15,000

Underlying: Class A Common Stock · 15,000 shares

Expires 2035-01-23

F1 · derivative.exercise_date: These options were granted on January 23, 2025, and will vest on January 1, 2026.

SEC source: 0001209191-24-005851 · doc4.xml · derivative · entry 1

Wolterman Dan · CIK 0001586330 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 79,200

Underlying: Class A Common Stock · 79,200 shares

Expires 2034-06-12

F1 · derivative.exercise_date: The shares underlying this option vest on the date of the Issuer's next regular annual stockholders meeting, subject to Mr. Wolterman's continued service through the applicable vesting date.

SEC source: 0000950170-24-008961 · ownership.xml · derivative · entry 1

Wolterman Dan · CIK 0001586330 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 15,000

Underlying: Class A Common Stock · 15,000 shares

Expires 2034-01-26

F1 · derivative.exercise_date: These options were granted on January 26, 2024, and will vest on January 1, 2025.

SEC source: 0001209191-23-048195 · doc4.xml · derivative · entry 10

Wolterman Dan · CIK 0001586330 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 4,816 shares

Expires not disclosed

F1 · derivative.exercise_price: Represented a contingent right to receive one share of the Issuer's common stock upon vesting.

F2 · derivative.exercise_date: Pursuant to the Agreement and Plan of Merger, dated as of February 8, 2023 (the "Merger Agreement"), by and among the Issuer, Globus Medical, Inc. ("Globus") and Zebra Merger Sub, Inc. ("Merger Sub"), Merger Sub merged with and into the Issuer, with the Issuer continuing as a wholly owned subsidiary of Globus. At the effective time of the merger, each restricted stock unit award became fully vested and was cancelled and converted automatically into the right to receive 0.75 shares of Class A common stock of Globus, par value $0.001 per share, and cash in lieu of fractional shares, in respect of each share of Issuer common stock underlying such award.

F2 · derivative.expiration_date: Pursuant to the Agreement and Plan of Merger, dated as of February 8, 2023 (the "Merger Agreement"), by and among the Issuer, Globus Medical, Inc. ("Globus") and Zebra Merger Sub, Inc. ("Merger Sub"), Merger Sub merged with and into the Issuer, with the Issuer continuing as a wholly owned subsidiary of Globus. At the effective time of the merger, each restricted stock unit award became fully vested and was cancelled and converted automatically into the right to receive 0.75 shares of Class A common stock of Globus, par value $0.001 per share, and cash in lieu of fractional shares, in respect of each share of Issuer common stock underlying such award.

SEC source: 0001209191-23-048195 · doc4.xml · derivative · entry 9

Wolterman Dan · CIK 0001586330 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 3,788 shares

Expires not disclosed

F1 · derivative.exercise_price: Represented a contingent right to receive one share of the Issuer's common stock upon vesting.

F2 · derivative.exercise_date: Pursuant to the Agreement and Plan of Merger, dated as of February 8, 2023 (the "Merger Agreement"), by and among the Issuer, Globus Medical, Inc. ("Globus") and Zebra Merger Sub, Inc. ("Merger Sub"), Merger Sub merged with and into the Issuer, with the Issuer continuing as a wholly owned subsidiary of Globus. At the effective time of the merger, each restricted stock unit award became fully vested and was cancelled and converted automatically into the right to receive 0.75 shares of Class A common stock of Globus, par value $0.001 per share, and cash in lieu of fractional shares, in respect of each share of Issuer common stock underlying such award.

F2 · derivative.expiration_date: Pursuant to the Agreement and Plan of Merger, dated as of February 8, 2023 (the "Merger Agreement"), by and among the Issuer, Globus Medical, Inc. ("Globus") and Zebra Merger Sub, Inc. ("Merger Sub"), Merger Sub merged with and into the Issuer, with the Issuer continuing as a wholly owned subsidiary of Globus. At the effective time of the merger, each restricted stock unit award became fully vested and was cancelled and converted automatically into the right to receive 0.75 shares of Class A common stock of Globus, par value $0.001 per share, and cash in lieu of fractional shares, in respect of each share of Issuer common stock underlying such award.

SEC source: 0001209191-23-048195 · doc4.xml · derivative · entry 8

Wolterman Dan · CIK 0001586330 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 2,702 shares

Expires not disclosed

F1 · derivative.exercise_price: Represented a contingent right to receive one share of the Issuer's common stock upon vesting.

F2 · derivative.exercise_date: Pursuant to the Agreement and Plan of Merger, dated as of February 8, 2023 (the "Merger Agreement"), by and among the Issuer, Globus Medical, Inc. ("Globus") and Zebra Merger Sub, Inc. ("Merger Sub"), Merger Sub merged with and into the Issuer, with the Issuer continuing as a wholly owned subsidiary of Globus. At the effective time of the merger, each restricted stock unit award became fully vested and was cancelled and converted automatically into the right to receive 0.75 shares of Class A common stock of Globus, par value $0.001 per share, and cash in lieu of fractional shares, in respect of each share of Issuer common stock underlying such award.

F2 · derivative.expiration_date: Pursuant to the Agreement and Plan of Merger, dated as of February 8, 2023 (the "Merger Agreement"), by and among the Issuer, Globus Medical, Inc. ("Globus") and Zebra Merger Sub, Inc. ("Merger Sub"), Merger Sub merged with and into the Issuer, with the Issuer continuing as a wholly owned subsidiary of Globus. At the effective time of the merger, each restricted stock unit award became fully vested and was cancelled and converted automatically into the right to receive 0.75 shares of Class A common stock of Globus, par value $0.001 per share, and cash in lieu of fractional shares, in respect of each share of Issuer common stock underlying such award.

SEC source: 0001209191-23-048195 · doc4.xml · derivative · entry 7

Wolterman Dan · CIK 0001586330 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 3,095 shares

Expires not disclosed

F1 · derivative.exercise_price: Represented a contingent right to receive one share of the Issuer's common stock upon vesting.

F2 · derivative.exercise_date: Pursuant to the Agreement and Plan of Merger, dated as of February 8, 2023 (the "Merger Agreement"), by and among the Issuer, Globus Medical, Inc. ("Globus") and Zebra Merger Sub, Inc. ("Merger Sub"), Merger Sub merged with and into the Issuer, with the Issuer continuing as a wholly owned subsidiary of Globus. At the effective time of the merger, each restricted stock unit award became fully vested and was cancelled and converted automatically into the right to receive 0.75 shares of Class A common stock of Globus, par value $0.001 per share, and cash in lieu of fractional shares, in respect of each share of Issuer common stock underlying such award.

F2 · derivative.expiration_date: Pursuant to the Agreement and Plan of Merger, dated as of February 8, 2023 (the "Merger Agreement"), by and among the Issuer, Globus Medical, Inc. ("Globus") and Zebra Merger Sub, Inc. ("Merger Sub"), Merger Sub merged with and into the Issuer, with the Issuer continuing as a wholly owned subsidiary of Globus. At the effective time of the merger, each restricted stock unit award became fully vested and was cancelled and converted automatically into the right to receive 0.75 shares of Class A common stock of Globus, par value $0.001 per share, and cash in lieu of fractional shares, in respect of each share of Issuer common stock underlying such award.

SEC source: 0001209191-23-048195 · doc4.xml · derivative · entry 6

Wolterman Dan · CIK 0001586330 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 2,577 shares

Expires not disclosed

F1 · derivative.exercise_price: Represented a contingent right to receive one share of the Issuer's common stock upon vesting.

F2 · derivative.exercise_date: Pursuant to the Agreement and Plan of Merger, dated as of February 8, 2023 (the "Merger Agreement"), by and among the Issuer, Globus Medical, Inc. ("Globus") and Zebra Merger Sub, Inc. ("Merger Sub"), Merger Sub merged with and into the Issuer, with the Issuer continuing as a wholly owned subsidiary of Globus. At the effective time of the merger, each restricted stock unit award became fully vested and was cancelled and converted automatically into the right to receive 0.75 shares of Class A common stock of Globus, par value $0.001 per share, and cash in lieu of fractional shares, in respect of each share of Issuer common stock underlying such award.

F2 · derivative.expiration_date: Pursuant to the Agreement and Plan of Merger, dated as of February 8, 2023 (the "Merger Agreement"), by and among the Issuer, Globus Medical, Inc. ("Globus") and Zebra Merger Sub, Inc. ("Merger Sub"), Merger Sub merged with and into the Issuer, with the Issuer continuing as a wholly owned subsidiary of Globus. At the effective time of the merger, each restricted stock unit award became fully vested and was cancelled and converted automatically into the right to receive 0.75 shares of Class A common stock of Globus, par value $0.001 per share, and cash in lieu of fractional shares, in respect of each share of Issuer common stock underlying such award.

SEC source: 0001209191-23-048195 · doc4.xml · derivative · entry 5

Wolterman Dan · CIK 0001586330 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 3,230 shares

Expires not disclosed

F1 · derivative.exercise_price: Represented a contingent right to receive one share of the Issuer's common stock upon vesting.

F2 · derivative.exercise_date: Pursuant to the Agreement and Plan of Merger, dated as of February 8, 2023 (the "Merger Agreement"), by and among the Issuer, Globus Medical, Inc. ("Globus") and Zebra Merger Sub, Inc. ("Merger Sub"), Merger Sub merged with and into the Issuer, with the Issuer continuing as a wholly owned subsidiary of Globus. At the effective time of the merger, each restricted stock unit award became fully vested and was cancelled and converted automatically into the right to receive 0.75 shares of Class A common stock of Globus, par value $0.001 per share, and cash in lieu of fractional shares, in respect of each share of Issuer common stock underlying such award.

F2 · derivative.expiration_date: Pursuant to the Agreement and Plan of Merger, dated as of February 8, 2023 (the "Merger Agreement"), by and among the Issuer, Globus Medical, Inc. ("Globus") and Zebra Merger Sub, Inc. ("Merger Sub"), Merger Sub merged with and into the Issuer, with the Issuer continuing as a wholly owned subsidiary of Globus. At the effective time of the merger, each restricted stock unit award became fully vested and was cancelled and converted automatically into the right to receive 0.75 shares of Class A common stock of Globus, par value $0.001 per share, and cash in lieu of fractional shares, in respect of each share of Issuer common stock underlying such award.

SEC source: 0001209191-23-048195 · doc4.xml · derivative · entry 4

Wolterman Dan · CIK 0001586330 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 2,130 shares

Expires not disclosed

F1 · derivative.exercise_price: Represented a contingent right to receive one share of the Issuer's common stock upon vesting.

F2 · derivative.exercise_date: Pursuant to the Agreement and Plan of Merger, dated as of February 8, 2023 (the "Merger Agreement"), by and among the Issuer, Globus Medical, Inc. ("Globus") and Zebra Merger Sub, Inc. ("Merger Sub"), Merger Sub merged with and into the Issuer, with the Issuer continuing as a wholly owned subsidiary of Globus. At the effective time of the merger, each restricted stock unit award became fully vested and was cancelled and converted automatically into the right to receive 0.75 shares of Class A common stock of Globus, par value $0.001 per share, and cash in lieu of fractional shares, in respect of each share of Issuer common stock underlying such award.

F2 · derivative.expiration_date: Pursuant to the Agreement and Plan of Merger, dated as of February 8, 2023 (the "Merger Agreement"), by and among the Issuer, Globus Medical, Inc. ("Globus") and Zebra Merger Sub, Inc. ("Merger Sub"), Merger Sub merged with and into the Issuer, with the Issuer continuing as a wholly owned subsidiary of Globus. At the effective time of the merger, each restricted stock unit award became fully vested and was cancelled and converted automatically into the right to receive 0.75 shares of Class A common stock of Globus, par value $0.001 per share, and cash in lieu of fractional shares, in respect of each share of Issuer common stock underlying such award.

SEC source: 0001209191-23-048195 · doc4.xml · derivative · entry 3

Wolterman Dan · CIK 0001586330 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 2,822 shares

Expires not disclosed

F1 · derivative.exercise_price: Represented a contingent right to receive one share of the Issuer's common stock upon vesting.

F2 · derivative.exercise_date: Pursuant to the Agreement and Plan of Merger, dated as of February 8, 2023 (the "Merger Agreement"), by and among the Issuer, Globus Medical, Inc. ("Globus") and Zebra Merger Sub, Inc. ("Merger Sub"), Merger Sub merged with and into the Issuer, with the Issuer continuing as a wholly owned subsidiary of Globus. At the effective time of the merger, each restricted stock unit award became fully vested and was cancelled and converted automatically into the right to receive 0.75 shares of Class A common stock of Globus, par value $0.001 per share, and cash in lieu of fractional shares, in respect of each share of Issuer common stock underlying such award.

F2 · derivative.expiration_date: Pursuant to the Agreement and Plan of Merger, dated as of February 8, 2023 (the "Merger Agreement"), by and among the Issuer, Globus Medical, Inc. ("Globus") and Zebra Merger Sub, Inc. ("Merger Sub"), Merger Sub merged with and into the Issuer, with the Issuer continuing as a wholly owned subsidiary of Globus. At the effective time of the merger, each restricted stock unit award became fully vested and was cancelled and converted automatically into the right to receive 0.75 shares of Class A common stock of Globus, par value $0.001 per share, and cash in lieu of fractional shares, in respect of each share of Issuer common stock underlying such award.

SEC source: 0001209191-23-048195 · doc4.xml · derivative · entry 2

Wolterman Dan · CIK 0001586330 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 4,230 shares

Expires not disclosed

F1 · derivative.exercise_price: Represented a contingent right to receive one share of the Issuer's common stock upon vesting.

F2 · derivative.exercise_date: Pursuant to the Agreement and Plan of Merger, dated as of February 8, 2023 (the "Merger Agreement"), by and among the Issuer, Globus Medical, Inc. ("Globus") and Zebra Merger Sub, Inc. ("Merger Sub"), Merger Sub merged with and into the Issuer, with the Issuer continuing as a wholly owned subsidiary of Globus. At the effective time of the merger, each restricted stock unit award became fully vested and was cancelled and converted automatically into the right to receive 0.75 shares of Class A common stock of Globus, par value $0.001 per share, and cash in lieu of fractional shares, in respect of each share of Issuer common stock underlying such award.

F2 · derivative.expiration_date: Pursuant to the Agreement and Plan of Merger, dated as of February 8, 2023 (the "Merger Agreement"), by and among the Issuer, Globus Medical, Inc. ("Globus") and Zebra Merger Sub, Inc. ("Merger Sub"), Merger Sub merged with and into the Issuer, with the Issuer continuing as a wholly owned subsidiary of Globus. At the effective time of the merger, each restricted stock unit award became fully vested and was cancelled and converted automatically into the right to receive 0.75 shares of Class A common stock of Globus, par value $0.001 per share, and cash in lieu of fractional shares, in respect of each share of Issuer common stock underlying such award.

SEC source: 0001209191-23-048195 · doc4.xml · derivative · entry 1

Wolterman Dan · CIK 0001586330 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 2,644 shares

Expires not disclosed

F1 · derivative.exercise_price: Represented a contingent right to receive one share of the Issuer's common stock upon vesting.

F2 · derivative.exercise_date: Pursuant to the Agreement and Plan of Merger, dated as of February 8, 2023 (the "Merger Agreement"), by and among the Issuer, Globus Medical, Inc. ("Globus") and Zebra Merger Sub, Inc. ("Merger Sub"), Merger Sub merged with and into the Issuer, with the Issuer continuing as a wholly owned subsidiary of Globus. At the effective time of the merger, each restricted stock unit award became fully vested and was cancelled and converted automatically into the right to receive 0.75 shares of Class A common stock of Globus, par value $0.001 per share, and cash in lieu of fractional shares, in respect of each share of Issuer common stock underlying such award.

F2 · derivative.expiration_date: Pursuant to the Agreement and Plan of Merger, dated as of February 8, 2023 (the "Merger Agreement"), by and among the Issuer, Globus Medical, Inc. ("Globus") and Zebra Merger Sub, Inc. ("Merger Sub"), Merger Sub merged with and into the Issuer, with the Issuer continuing as a wholly owned subsidiary of Globus. At the effective time of the merger, each restricted stock unit award became fully vested and was cancelled and converted automatically into the right to receive 0.75 shares of Class A common stock of Globus, par value $0.001 per share, and cash in lieu of fractional shares, in respect of each share of Issuer common stock underlying such award.

SEC source: 0001209191-23-048416 · doc4.xml · derivative · entry 2

Wolterman Dan · CIK 0001586330 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 15,000

Underlying: Class A Common Stock · 15,000 shares

Expires 2033-09-01

F2 · derivative.exercise_date: These options were granted on September 1, 2023, and vest over a four-year period with one-fourth (1/4) of the options granted vesting on September 1, 2024, the first anniversary of the vesting commencement date, and the balance of the options granted vesting ratably on a monthly basis over the following 36 months.

SEC source: 0001209191-23-048416 · doc4.xml · nonDerivative · entry 1

Wolterman Dan · CIK 0001586330 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 24,025

F1 · price: Pursuant to the Agreement and Plan of Merger, dated as of February 8, 2023 (the "Merger Agreement"), by and among the Issuer, NuVasive, Inc. ("NuVasive") and Zebra Merger Sub, Inc. ("Merger Sub"), Merger Sub merged with and into NuVasive (the "Merger"), with NuVasive continuing as a wholly owned subsidiary of the Issuer. At the effective time of the Merger, each NuVasive restricted stock unit award was accelerated, cancelled and converted automatically into the right to receive 0.75 shares of Class A common stock of Issuer, par value $0.001 per share, and cash in lieu of fractional shares, in respect of each share of NuVasive common stock underlying such award.

SEC source: 0001209191-23-036461 · doc4.xml · derivative · entry 1

Wolterman Dan · CIK 0001586330 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 4,816

Underlying: Common Stock · 4,816 shares

Expires not disclosed

F1 · security: Each Restricted Stock Unit ("RSU") represents the right to receive one share of the Issuer's common stock upon vesting.

F2 · derivative.exercise_date: Award of RSUs pursuant to Issuer's Board of Director's compensation policies granted under Issuer's 2014 Equity Incentive Plan. The grant will vest in full on the first to occur of (1) Issuer's 2024 Annual Meeting of Stockholders, or (2) the one-year anniversary of the date of grant. Settlement of this award has been deferred until the Reporting Person's separation from service with the Issuer's Board of Directors.

F3 · derivative.exercise_date: On February 8, 2023, Issuer entered into an Agreement and Plan of Merger (the "Merger Agreement") with Globus Medical, Inc. ("Globus Medical") and Zebra Merger Sub, Inc. ("Merger Sub"), a wholly owned subsidiary of Globus Medical. The Merger Agreement provides, among other things, that subject to the satisfaction or waiver of the conditions set forth therein, Merger Sub will merge with and into Issuer (the "Merger"), with Issuer surviving the Merger as a wholly owned subsidiary of Globus Medical. Pursuant to the Merger Agreement, at the effective time of the Merger (the "Effective Time"), each RSU outstanding immediately prior to the Effective Time held by the Reporting Person will fully vest and be cancelled and converted automatically into the right to receive (without interest) 0.75 fully paid and non-assessable shares of Class A common stock of Globus Medical (and cash in lieu of any fractional shares) in respect of each share of Issuer's common stock underlying such RSU.

F2 · derivative.expiration_date: Award of RSUs pursuant to Issuer's Board of Director's compensation policies granted under Issuer's 2014 Equity Incentive Plan. The grant will vest in full on the first to occur of (1) Issuer's 2024 Annual Meeting of Stockholders, or (2) the one-year anniversary of the date of grant. Settlement of this award has been deferred until the Reporting Person's separation from service with the Issuer's Board of Directors.

F3 · derivative.expiration_date: On February 8, 2023, Issuer entered into an Agreement and Plan of Merger (the "Merger Agreement") with Globus Medical, Inc. ("Globus Medical") and Zebra Merger Sub, Inc. ("Merger Sub"), a wholly owned subsidiary of Globus Medical. The Merger Agreement provides, among other things, that subject to the satisfaction or waiver of the conditions set forth therein, Merger Sub will merge with and into Issuer (the "Merger"), with Issuer surviving the Merger as a wholly owned subsidiary of Globus Medical. Pursuant to the Merger Agreement, at the effective time of the Merger (the "Effective Time"), each RSU outstanding immediately prior to the Effective Time held by the Reporting Person will fully vest and be cancelled and converted automatically into the right to receive (without interest) 0.75 fully paid and non-assessable shares of Class A common stock of Globus Medical (and cash in lieu of any fractional shares) in respect of each share of Issuer's common stock underlying such RSU.

SEC source: 0001209191-23-036341 · doc4.xml · derivative · entry 2

Wolterman Dan · CIK 0001586330 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 85,000

Underlying: Class A Common Stock · 85,000 shares

Expires 2023-06-09

F2 · derivative.exercise_date: The shares underlying this option vest as to 50% on June 9, 2024 and the remaining 50% on June 9, 2025, subject to Mr. Wolterman's continued service through the applicable vesting date.

SEC source: 0001209191-23-036341 · doc4.xml · derivative · entry 1

Wolterman Dan · CIK 0001586330 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 112,000

Underlying: Class A Common Stock · 112,000 shares

Expires 2033-06-09

F1 · derivative.exercise_date: The shares underlying this option vest on the date of the Issuer's next regular annual stockholders meeting, subject to Mr. Wolterman's continued service through the applicable vesting date.

SEC source: 0001209191-23-040601 · doc4a.xml · derivative · entry 2

Wolterman Dan · CIK 0001586330 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 85,000

Underlying: Class A Common Stock · 85,000 shares

Expires 2033-06-09

F2 · derivative.exercise_date: The shares underlying this option vest as to 50% on June 9, 2024 and the remaining 50% on June 9, 2025, subject to Mr. Wolterman's continued service through the applicable vesting date.

SEC source: 0001209191-23-040601 · doc4a.xml · derivative · entry 1

Wolterman Dan · CIK 0001586330 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 112,000

Underlying: Class A Common Stock · 112,000 shares

Expires 2033-06-09

F1 · derivative.exercise_date: The shares underlying this option vest on the date of the Issuer's next regular annual stockholders meeting, subject to Mr. Wolterman's continued service through the applicable vesting date.

SEC source: 0001209191-22-036281 · doc4.xml · derivative · entry 1

Wolterman Dan · CIK 0001586330 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 85,345

Underlying: Class A Common Stock · 85,345 shares

Expires 2032-06-09

F1 · derivative.exercise_date: The shares underlying this option vest on the date of the Issuer's next regular annual stockholders meeting, subject to Mr. Wolterman's continued service through the applicable vesting date.

SEC source: 0001209191-22-028952 · doc4.xml · derivative · entry 1

Wolterman Dan · CIK 0001586330 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,788

Underlying: Common Stock · 3,788 shares

Expires not disclosed

F1 · security: Each Restricted Stock Unit ("RSU") represents the right to receive one share of the Issuer's common stock upon vesting.

F2 · derivative.exercise_date: Award of RSUs pursuant to Issuer's Board of Director's compensation policies granted under Issuer's 2014 Equity Incentive Plan. The grant will vest in full on the first to occur of (1) Issuer's 2023 Annual Meeting of Stockholders, or (2) the one-year anniversary of the date of grant. Settlement of this award has been deferred until the Reporting Person's separation from service with the Issuer's Board of Directors.

F2 · derivative.expiration_date: Award of RSUs pursuant to Issuer's Board of Director's compensation policies granted under Issuer's 2014 Equity Incentive Plan. The grant will vest in full on the first to occur of (1) Issuer's 2023 Annual Meeting of Stockholders, or (2) the one-year anniversary of the date of grant. Settlement of this award has been deferred until the Reporting Person's separation from service with the Issuer's Board of Directors.

SEC source: 0001104659-21-153335 · tm2135698-17_4seq1.xml · nonDerivative · entry 1

Wolterman Dan · CIK 0001586330 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 16,483

F1 · shares: Consists of restricted stock units ("RSUs"). Each RSU represents the right to receive one share of common stock upon vesting. The RSUs vest in equal annual installments over three years beginning on December 23, 2022, subject to Mr. Wolterman's continued service through the applicable vesting date.

SEC source: 0001104659-22-002891 · tm222483-6_4aseq1.xml · nonDerivative · entry 1

Wolterman Dan · CIK 0001586330 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 19,586

F1 · shares: Consists of restricted stock units ("RSUs"). Each RSU represents the right to receive one share of common stock upon vesting. The RSUs vest in equal annual installments over three years beginning on December 23, 2022, subject to Mr. Wolterman's continued service through the applicable vesting date.

SEC source: 0001209191-21-034563 · doc4.xml · derivative · entry 1

Wolterman Dan · CIK 0001586330 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,702

Underlying: Common Stock · 2,702 shares

Expires not disclosed

F1 · security: Each Restricted Stock Unit ("RSU") represents the right to receive one share of the Issuer's common stock upon vesting.

F2 · derivative.exercise_date: Award of RSUs pursuant to Issuer's Board of Director's compensation policies granted under Issuer's 2014 Equity Incentive Plan. The grant will vest in full on the first to occur of (1) Issuer's 2022 Annual Meeting of Stockholders, or (2) the one-year anniversary of the date of grant. Settlement of this award has been deferred until the Reporting Person's separation from service with the Issuer's Board of Directors.

F2 · derivative.expiration_date: Award of RSUs pursuant to Issuer's Board of Director's compensation policies granted under Issuer's 2014 Equity Incentive Plan. The grant will vest in full on the first to occur of (1) Issuer's 2022 Annual Meeting of Stockholders, or (2) the one-year anniversary of the date of grant. Settlement of this award has been deferred until the Reporting Person's separation from service with the Issuer's Board of Directors.

SEC source: 0001209191-20-033010 · doc4.xml · derivative · entry 1

Wolterman Dan · CIK 0001586330 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,095

Underlying: Common Stock · 3,095 shares

Expires not disclosed

F1 · security: Each Restricted Stock Unit ("RSU") represents the right to receive one share of the Issuer's common stock upon vesting.

F2 · derivative.exercise_date: Award of RSUs pursuant to Issuer's Board of Director's compensation policies granted under Issuer's 2014 Equity Incentive Plan. The grant will vest in full on the first to occur of (1) Issuer's 2021 Annual Meeting of Stockholders, or (2) the one-year anniversary of the date of grant. Settlement of this award has been deferred until the Reporting Person's separation from service with the Issuer's Board of Directors.

F2 · derivative.expiration_date: Award of RSUs pursuant to Issuer's Board of Director's compensation policies granted under Issuer's 2014 Equity Incentive Plan. The grant will vest in full on the first to occur of (1) Issuer's 2021 Annual Meeting of Stockholders, or (2) the one-year anniversary of the date of grant. Settlement of this award has been deferred until the Reporting Person's separation from service with the Issuer's Board of Directors.

SEC source: 0001209191-19-029067 · doc4.xml · derivative · entry 1

Wolterman Dan · CIK 0001586330 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,577

Underlying: Common Stock · 2,577 shares

Expires not disclosed

F1 · security: Each Restricted Stock Unit ("RSU") represents the right to receive one share of the Issuer's common stock upon vesting.

F2 · derivative.exercise_date: Award of RSUs pursuant to Issuer's Board of Director's compensation policies granted under Issuer's 2014 Equity Incentive Plan. The grant will vest in full on the first to occur of (1) Issuer's 2020 Annual Meeting of Stockholders, or (2) the one-year anniversary of the date of grant. Settlement of this award has been deferred until the Reporting Person's separation from service with the Issuer's Board of Directors.

F2 · derivative.expiration_date: Award of RSUs pursuant to Issuer's Board of Director's compensation policies granted under Issuer's 2014 Equity Incentive Plan. The grant will vest in full on the first to occur of (1) Issuer's 2020 Annual Meeting of Stockholders, or (2) the one-year anniversary of the date of grant. Settlement of this award has been deferred until the Reporting Person's separation from service with the Issuer's Board of Directors.

SEC source: 0001209191-18-055989 · doc4.xml · nonDerivative · entry 1

Wolterman Dan · CIK 0001586330 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

F1 · price: These securities were restricted stock units ("RSUs"), each of which represented a contingent right to receive one share of the Issuer's Common Stock.

F2 · price: The RSUs were cancelled pursuant to that certain Agreement and Plan of Merger between the Issuer, Stryker Corporation and Accipiter Corp., dated as of September 10, 2018, in exchange for an amount in cash per underlying share equal to $7.40 per share, without interest, subject to any required withholding of taxes.

SEC source: 0001104659-18-039934 · a4.xml · nonDerivative · entry 1

Wolterman Dan · CIK 0001586330 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 49,126

F1 · shares: Represents an initial restricted stock unit (RSU) award issued pursuant to the Issuer's Outside Director Compensation Policy. Each RSU represents a contingent right to receive one share of the Issuer's Common Stock upon settlement. 100% of the RSUs vest on June 11, 2019. The Reporting Person has elected to defer the receipt of the shares underlying the RSUs until the earlier of the Reporting Person's separation from service as a director or upon a "change of control" of the Issuer, pursuant to the Issuer's Restricted Stock Unit Deferral Program for Outside Directors.

SEC source: 0001209191-18-028420 · doc4.xml · derivative · entry 1

Wolterman Dan · CIK 0001586330 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,230

Underlying: Common Stock · 3,230 shares

Expires not disclosed

F1 · security: Each Restricted Stock Unit ("RSU") represents the right to receive one share of the Issuer's common stock upon vesting.

F2 · derivative.exercise_date: Award of RSUs pursuant to Issuer's Board of Director's compensation policies granted under Issuer's 2014 Equity Incentive Plan. The grant will vest in full on the first to occur of (1) Issuer's 2019 Annual Meeting of Stockholders, or (2) the one-year anniversary of the date of grant. Settlement of this award has been deferred until the Reporting Person's separation from service with the Issuer's Board of Directors.

F2 · derivative.expiration_date: Award of RSUs pursuant to Issuer's Board of Director's compensation policies granted under Issuer's 2014 Equity Incentive Plan. The grant will vest in full on the first to occur of (1) Issuer's 2019 Annual Meeting of Stockholders, or (2) the one-year anniversary of the date of grant. Settlement of this award has been deferred until the Reporting Person's separation from service with the Issuer's Board of Directors.

SEC source: 0001104659-17-055907 · a4.xml · nonDerivative · entry 1

Wolterman Dan · CIK 0001586330 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 14,880

F1 · shares: Represents an initial restricted stock unit (RSU) award issued pursuant to the Issuer's Outside Director Compensation Policy. Each RSU represents a contingent right to receive one share of the Issuer's Common Stock upon settlement. 100% of the RSUs vest on September 5, 2018. The Reporting Person has elected to defer the receipt of the shares underlying the RSUs until the earlier of the Reporting Person's separation from service as a director or upon a "change of control" of the Issuer, pursuant to the Issuer's Restricted Stock Unit Deferral Program for Outside Directors.

SEC source: 0001209191-17-034410 · doc4.xml · derivative · entry 1

Wolterman Dan · CIK 0001586330 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,130

Underlying: Common Stock · 2,130 shares

Expires not disclosed

F1 · security: Each Restricted Stock Unit ("RSU") represents the right to receive one share of the Issuer's common stock upon vesting.

F2 · derivative.exercise_date: Award of RSUs pursuant to Issuer's Board of Director's compensation policies granted under Issuer's 2014 Equity Incentive Plan. The grant will vest in full on the first to occur of (1) Issuer's 2018 Annual Meeting of Stockholders, or (2) the one-year anniversary of the date of grant. Settlement of this award has been deferred until the Reporting Person's separation from service with the Issuer's Board of Directors.

F2 · derivative.expiration_date: Award of RSUs pursuant to Issuer's Board of Director's compensation policies granted under Issuer's 2014 Equity Incentive Plan. The grant will vest in full on the first to occur of (1) Issuer's 2018 Annual Meeting of Stockholders, or (2) the one-year anniversary of the date of grant. Settlement of this award has been deferred until the Reporting Person's separation from service with the Issuer's Board of Directors.